Adaptimmune Therapeutics (ADAP) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Adaptimmune Therapeutics Revenue Highlights


Latest Revenue (Y)

$60.28M

Latest Revenue (Q)

$128.37M

Main Segment (Y)

Development revenue

Adaptimmune Therapeutics Revenue by Period


Adaptimmune Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$60.28M122.05%
2022-12-31$27.15M341.50%
2021-12-31$6.15M55.36%
2020-12-31$3.96M252.76%
2019-12-31$1.12M-98.11%
2018-12-31$59.51M57.28%
2017-12-31$37.83M166.47%
2016-12-31$14.20M32.43%
2015-06-30$10.72M1673.21%
2014-06-30$604.63K100.00%
2013-06-30--

Adaptimmune Therapeutics generated $60.28M in revenue during NA 2023, up 122.05% compared to the previous quarter, and up 101.30% compared to the same period a year ago.

Adaptimmune Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$128.37M2160.91%
2024-03-31$5.68M2336.82%
2023-12-31$233.01K-96.82%
2023-09-30$7.32M42.67%
2023-06-30$5.13M-89.22%
2023-03-31$47.60M331.64%
2022-12-31$11.03M57.39%
2022-09-30$7.01M26.53%
2022-06-30$5.54M54.91%
2022-03-31$3.58M152.29%
2021-12-31$1.42M17.79%
2021-09-30$1.20M-61.13%
2021-06-30$3.10M613.13%
2021-03-31$434.00K-71.11%
2020-12-31$1.50M25.90%
2020-09-30$1.19M137.65%
2020-06-30$502.00K-34.03%
2020-03-31$761.00K4.53%
2019-12-31$728.00K207.17%
2019-09-30$237.00K50.96%
2019-06-30$157.00K100.00%
2019-03-31--100.00%
2018-12-31$1.48M-96.37%
2018-09-30$40.79M351.34%
2018-06-30$9.04M10.27%
2018-03-31$8.20M91.94%
2017-12-31$4.27M-84.29%
2017-09-30$27.18M672.08%
2017-06-30$3.52M23.24%
2017-03-31$2.86M-66.53%
2016-12-31$8.54M253.31%
2016-09-30$2.42M636.59%
2016-06-30$328.00K-88.76%
2016-03-31$2.92M-25.94%
2015-09-30$3.94M100.00%
2015-03-31--100.00%
2014-12-31$2.27M47.92%
2014-09-30$1.53M-

Adaptimmune Therapeutics generated $128.37M in revenue during Q2 2024, up 2160.91% compared to the previous quarter, and up 269.69% compared to the same period a year ago.

Adaptimmune Therapeutics Revenue Breakdown


Adaptimmune Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Development revenue$60.28M$27.15M$6.15M--
Development And Service---$3.96M$1.12M

Adaptimmune Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Development revenue (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Dec 18Sep 18Jun 18
Development revenue$7.55M$5.13M$47.60M$11.03M$7.01M$5.54M$3.58M$1.20M------------
Development And Service--------$3.10M$434.00K$1.50M$1.19M$502.00K$761.00K$728.00K$237.00K$157.00K$1.48M$1.68M$9.04M
License And Service------------------$39.11M-

Adaptimmune Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Development revenue (100.00%).

Adaptimmune Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
SGMOSangamo Therapeutics$176.23M$356.00K
ADAPAdaptimmune Therapeutics$60.28M$128.37M
PIRSPieris Pharmaceuticals$42.81M-
AGIOAgios Pharmaceuticals$26.82M$8.96M
MREOMereo BioPharma Group$10.00M-
STOKStoke Therapeutics$8.78M$4.22M
AFMDAffimed$8.28M$155.00K
PLRXPliant Therapeutics$1.58M-
FIXXQ32 Bio$1.16M-
CRVSCorvus Pharmaceuticals--
APTOAptose Biosciences--
BDTXBlack Diamond Therapeutics--
INKTMiNK Therapeutics--
PDSBPDS Bio--
NKTXNkarta--
LPTXLeap Therapeutics--
ACETAdicet Bio--

ADAP Revenue FAQ


Adaptimmune Therapeutics's yearly revenue for 2023 was $60.28M, representing an increase of 122.05% compared to 2022. The company's yearly revenue for 2022 was $27.15M, representing an increase of 341.50% compared to 2021. ADAP's yearly revenue for 2021 was $6.15M, representing an increase of 55.36% compared to 2020.

Adaptimmune Therapeutics's quarterly revenue for Q2 2024 was $128.37M, a 2160.91% increase from the previous quarter (Q1 2024), and a 2402.43% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $5.68M, a 2336.82% increase from the previous quarter (Q4 2023), and a -88.07% decrease year-over-year (Q1 2023). ADAP's quarterly revenue for Q4 2023 was $233.01K, a -96.82% decrease from the previous quarter (Q3 2023), and a -97.89% decrease year-over-year (Q4 2022).

Adaptimmune Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 880.34%, and for the last 5 years (2019-2023) was 5272.64%.

Adaptimmune Therapeutics's revenue streams in c 23 are Development revenue

For the fiscal year ending Dec 23, the largest source of revenue of Adaptimmune Therapeutics was Development revenue. This segment made a revenue of $60.28M, representing 100.00% of the company's total revenue.